Your browser doesn't support javascript.
loading
Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial.
Wei, L-H; Su, Y-Y; Hu, Y-M; Li, R-C; Chen, W; Pan, Q-J; Zhang, X; Zhao, F-H; Zhao, Y-Q; Li, Q; Hong, Y; Zhao, C; Li, M-Q; Liu, W-Y; Li, C-H; Guo, D-P; Ke, L-D; Lin, B-Z; Lin, Z-J; Chen, S; Sheng, W; Zheng, Z-Z; Zhuang, S-J; Zhu, F-C; Pan, H-R; Li, Y-M; Huang, S-J; Zhang, J; Qiao, Y-L; Wu, T; Xia, N-S.
Afiliação
  • Wei LH; Peking University People's Hospital, Beijing, China.
  • Su YY; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Hu YM; Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing, Jiangsu, China.
  • Li RC; Guangxi Centre for Disease Control and Prevention, Nanning, Guangxi, China.
  • Chen W; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.
  • Pan QJ; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.
  • Zhang X; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.
  • Zhao FH; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.
  • Zhao YQ; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.
  • Li Q; Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, Guangdong, China.
  • Hong Y; The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
  • Zhao C; Peking University People's Hospital, Beijing, China.
  • Li MQ; Liuzhou Centre for Disease Control and Prevention, Liuzhou, Guangxi, China.
  • Liu WY; Funing Centre for Disease Control and Prevention, Funing, Jiangsu, China.
  • Li CH; Xinmi Maternal and Child Health Hospital, Xinmi, Henan, China.
  • Guo DP; Yangcheng Maternal and Child Health Hospital, Yangcheng, Shanxi, China.
  • Ke LD; Fengning Hospital of Traditional Chinese Medicine, Fengning, Hebei, China.
  • Lin BZ; Xiamen Innovax Biotech Company, Xiamen, Fujian, China.
  • Lin ZJ; Xiamen Innovax Biotech Company, Xiamen, Fujian, China.
  • Chen S; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Sheng W; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zheng ZZ; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zhuang SJ; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zhu FC; Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing, Jiangsu, China.
  • Pan HR; Xiamen Innovax Biotech Company, Xiamen, Fujian, China.
  • Li YM; Xiamen Innovax Biotech Company, Xiamen, Fujian, China.
  • Huang SJ; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zhang J; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Qiao YL; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China. Electronic address: qiaoy@cicams.ac.cn.
  • Wu T; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China. Electronic address:
  • Xia NS; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
Clin Microbiol Infect ; 26(8): 1069-1075, 2020 Aug.
Article em En | MEDLINE | ID: mdl-31904566
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Papillomavirus / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Anticorpos Neutralizantes Tipo de estudo: Clinical_trials / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Papillomavirus / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Anticorpos Neutralizantes Tipo de estudo: Clinical_trials / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2020 Tipo de documento: Article